These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 19435458)

  • 1. CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation.
    Wang J
    Expert Rev Mol Diagn; 2009 May; 9(4):383-90. PubMed ID: 19435458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies.
    Anglicheau D; Legendre C; Thervet E
    Transplant Proc; 2007 Sep; 39(7):2142-4. PubMed ID: 17889118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.
    Anglicheau D; Legendre C; Beaune P; Thervet E
    Pharmacogenomics; 2007 Jul; 8(7):835-49. PubMed ID: 18240909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
    Barrera-Pulido L; Aguilera-García I; Docobo-Pérez F; Alamo-Martínez JM; Pareja-Ciuró F; Nuñez-Roldán A; Gómez-Bravo MA; Bernardos-Rodríguez A
    Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome P450 3A polymorphisms and immunosuppressive drugs.
    Thervet E; Legendre C; Beaune P; Anglicheau D
    Pharmacogenomics; 2005 Jan; 6(1):37-47. PubMed ID: 15723604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
    Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic factors for individual administration of immunosuppressants in organ transplantation.
    Yu SF; Wu LH; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):337-44. PubMed ID: 16911928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome.
    Mourad M; Wallemacq P; De Meyer M; Malaise J; De Pauw L; Eddour DC; Goffin E; Lerut J; Haufroid V
    Transplantation; 2008 Apr; 85(7 Suppl):S19-24. PubMed ID: 18401258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tada H; Tsuchiya N; Satoh S; Kagaya H; Li Z; Sato K; Miura M; Suzuki T; Kato T; Habuchi T
    Transplant Proc; 2005 May; 37(4):1730-2. PubMed ID: 15919447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
    Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
    Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients.
    Masuda S; Inui K
    Pharmacol Ther; 2006 Oct; 112(1):184-98. PubMed ID: 16759707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients.
    Tirelli S; Ferraresso M; Ghio L; Meregalli E; Martina V; Belingheri M; Mattiello C; Torresani E; Edefonti A
    Med Sci Monit; 2008 May; 14(5):CR251-254. PubMed ID: 18443548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients.
    Mendes J; Martinho A; Simoes O; Mota A; Breitenfeld L; Pais L
    Transplant Proc; 2009 Apr; 41(3):840-2. PubMed ID: 19376366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics in solid organ transplantation: current status and future directions.
    de Jonge H; Kuypers DR
    Transplant Rev (Orlando); 2008 Jan; 22(1):6-20. PubMed ID: 18631854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.
    Thervet E; Anglicheau D; King B; Schlageter MH; Cassinat B; Beaune P; Legendre C; Daly AK
    Transplantation; 2003 Oct; 76(8):1233-5. PubMed ID: 14578760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
    Press RR; Ploeger BA; den Hartigh J; van der Straaten T; van Pelt J; Danhof M; de Fijter JW; Guchelaar HJ
    Ther Drug Monit; 2009 Apr; 31(2):187-97. PubMed ID: 19258929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphisms and individualized tacrolimus dosing.
    López-Montenegro Soria MA; Kanter Berga J; Beltrán Catalán S; Milara Payá J; Pallardó Mateu LM; Jiménez Torres NV
    Transplant Proc; 2010 Oct; 42(8):3031-3. PubMed ID: 20970601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.
    Zhao Y; Song M; Guan D; Bi S; Meng J; Li Q; Wang W
    Transplant Proc; 2005; 37(1):178-81. PubMed ID: 15808586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?
    van Gelder T; Hesselink DA
    Clin Pharmacol Ther; 2010 Jun; 87(6):640-1. PubMed ID: 20485320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.